LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

ClinicalTrials.gov ID: NCT06232408

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06232408. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to identify a safe and tolerated dose and schedule of the orally administered PLK4 inhibitor RP-1664. In addition, this study will examine the pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RP-1664 in advanced solid tumors.

Study identification

NCT ID: NCT06232408
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Repare Therapeutics; Industry
Enrollment: 29 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

RP-1664 Drug

Drug

Eligibility (public fields only)

Age range: 12 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 14, 2024 (Actual)
Primary completion: Aug 27, 2025 (Actual)
Completion: Aug 27, 2025 (Actual)
Last update posted: Nov 21, 2025

2024 – 2025

United States locations

U.S. sites: 4
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Participating Site 1025	San Francisco	California	94143	—
Participating Site 1012	New Haven	Connecticut	06519	—
Participating Site 1008	New York	New York	10032	—
Participating Site 1004	New York	New York	10065	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06232408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 21, 2025 · Synced Nov 14, 2026